Toboroz
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849· 3. fázis· argenx· Forrás
Contact: Ichiro Horie, MD
Toboroz
Pemafibrate for Symptomatic ICAS RCT
NCT07562178· Tokyo Women's Medical University· Forrás
Contact: Yohei Tateishi
Toboroz
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
NCT07623616· 2. fázis· Kyowa Kirin Co., Ltd.· Forrás
Contact: Kyowa Kirin, Inc.
Toboroz
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· 3. fázis· Taiho Oncology, Inc.· Forrás
Contact: Taiho Oncology, Inc.
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: hisamitsu miyaaki (principal investigator)
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Fut, nem toboroz
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
NCT06970665· 4. fázis· Astellas Pharma Inc· Forrás
Toboroz
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373· 2. fázis· Swedish Orphan Biovitrum· Forrás
Contact: Study Physician
Toboroz
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás
Contact: Takemoto Shinnosuke, Site 0687
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949· 3. fázis· Amgen· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Contact: Kayoko Matsushima (principal investigator)
Fut, nem toboroz
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408· 3. fázis· Amgen· Forrás
Toboroz
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
NCT07075328· 1/2. fázis· Otsuka Medical Devices Co., Ltd. Japan· Forrás
Contact: Kentaro Ishinabe
Toboroz
Zephyr Valve Japan Post-Marketing Surveillance
NCT06332885· Pulmonx Corporation· Forrás
Contact: Keitaro Matsumoto, MD
Fut, nem toboroz
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299· 1. fázis· Kyowa Kirin Co., Ltd.· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Contact: Takemoto Shinnosuke (principal investigator)
Fut, nem toboroz
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972· 2. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Fut, nem toboroz
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500· 3. fázis· Viatris Innovation GmbH· Forrás
Fut, nem toboroz
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095· 3. fázis· Janssen-Cilag Ltd.· Forrás
Fut, nem toboroz
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· 2/3. fázis· Biogen· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555· 1/2. fázis· Sumitomo Pharma America, Inc.· Forrás
Contact: Yasushi Miyazaki
Fut, nem toboroz
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· 3. fázis· Amgen· Forrás
Toboroz
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567· 3. fázis· Biogen· Forrás
Toboroz
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921· European Foundation for Study of Chronic Liver Failure· Forrás
Contact: Takanobu Hara
Toboroz
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994· 3. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás
Contact: Peter Galle, Prof. Dr.
Fut, nem toboroz
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
NCT04703192· 2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Toboroz
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
NCT04608110· 1. fázis· Taiho Pharmaceutical Co., Ltd.· Forrás
Contact: Hematology
Fut, nem toboroz
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484· 3. fázis· ADC Therapeutics S.A.· Forrás
Fut, nem toboroz
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· 3. fázis· Actelion· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623· North East Japan Study Group· Forrás
Fut, nem toboroz
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Phase III Trial of Stage I Ovarian Cancer After Surgery
NCT04063527· 3. fázis· Japanese Gynecologic Oncology Group· Forrás
Contact: Kiyonori Miura